Fiji Kava (ASX:FIJ)

Fiji Kava (ASX:FIJ) is a medicinal kava company which offers a plant-based alternative for the treatment of anxiety, insomnia, stress and muscle tension. Kava is made from the ground roots of the plant Piper Methysticum, which is a crop native to the South Pacific and traditionally consumed by Pacific Islanders for its relaxing effects.

Fiji Kava currently produces a range of high-quality medical kava products under the brand Taki Mai in Fiji. The company is dedicated to providing products that are tracked and traced from farm to shelf. Fiji Kava is developing proprietary profiling of specific kava cultivars with specific chemotype and kavalactone profiles to target anxiety, stress, insomnia, and muscle relaxation.

Board and Management


Dr Andrew Kelly
Non-executive Chairman

Dr Andrew Kelly is Executive Director and Co-Founder of BioPacific Partners, a biotech investment and consulting firm focused on providing new product development services to many of the world’s largest pharmaceutical and consumer health companies. He has a PhD with management training and is broadly experienced and networked across the Australian biotech scene. His 35-year career spans the spectrum from discovery science to commercial success, focusing in equal measures on research, commercialisation and investment.

Starting with a Bachelor of Veterinary Science degree in the late 1970s, Dr Kelly engaged in life science research and development in Australia and Canada, including Masters and PhD degrees, during the 1980s. He then led three separate research institutes – two in Australia and one in New Zealand, during the years 1992-2002.

Following that period, Dr Kelly led New Product Development for the large New Zealand research and development organisation, AgResearch, including deep engagement with start-ups and fund-raising. In 2005, Dr Kelly co-founded BioPacific Ventures, the first specialist venture fund focused across the spectrum of health, food and agriculture in Australia, which he led for 10 years. In 2014, he co-founded BioPacific Partners, partnering with some of the largest global companies investing and engaging with Australian innovation.

He is currently Executive director of BioPacific Partners Ltd (NZ), BioPacific Investments Ltd (NZ) and BioPacific Partners Pty Ltd (Australia) and has previously been Director of Focus Genetics Ltd (NZ), Horizon Science Ltd (AU), BioPacific Ventures Ltd (NZ), Anzamune Ltd (NZ), CMP Therapeutics Ltd (UK), Wool Equities (NZX listed), Encoate Ltd (NZ), Cleveland Biosensors Ltd (AU), InnerVision Ltd (NZ), Ultrafine Merino company Ltd (NZ), Velvet Antler Research New Zealand Ltd (NZ).

Zane Yoshida
Managing Director

Mr Yoshida is the founder and CEO of South Pacific Elixirs Pte Ltd (SPE Singapore). Mr Yoshida was born and raised in the Fiji Islands. He is extremely passionate about kava and understands its benefits first hand, having had his first kava ceremony 30 years ago.

As the former co-founder and Managing Director of Styrotex (Asia Pacific) Sdn Bhd, Zane successfully commercialised innovative technology in the plastics industry which he also co-patented. He established a joint venture with a Malaysian public company, and set up companies in Shanghai and Suzhou through joint ventures and strategic acquisitions to manufacture products for supply to multinational electronics companies throughout China.

Zane was also responsible for establishing strategic partnerships in Thailand and South Korea via license agreements, as well as distribution partnerships in Singapore and India. He holds a Bachelor’s degree in Mechanical Technology, a Postgraduate Diploma in IT and a Master’s Degree in Business Administration (2002) from the Queensland University of Technology in Australia.

Stephen Copplin
Executive Director

Mr Copplin has been a Director of South Pacific Elixirs Pte Ltd (SPE Singapore) since early in its inception. Mr Copplin is a Fellow of the Australian Institute of Company Directors, a Fellow Certified Practicing Accountant, a former Fellow of the Taxation Institute of Australia and recently completed 17 years as an Adjunct Professor at the University of Queensland in the Business School and continues to be an Adjunct Professor in the IT and Electrical Engineering School. His current board roles are Chair, Scarpar Holdings Limited (HK), Director and Chair Finance and Risk Committee Gallipoli Medicinal Research Foundation.

His past roles have included Chair Briz 31 Ltd, Chair Insurance Finance Australia and New Zealand, Chair Sheldon College foundation Limited, Director Helping Hands Childcare Network, Director and Chair Audit and Risk Committee Queensland Museum, Founder and Chair CFO Centre Pty Ltd. Mr Copplin is also an experienced Angel Investor, being a founding member of the ABOL-sponsored Sydney Angels and a founder of Brisbane Angels.